# Serological Surveillance of Betacoronaviruses in Bat Guano Collectors: Pre-COVID-19 Pandemic and Post-SARS-CoV-2 Emergence

**Authors:** Sasiprapa Ninwattana, Spencer L. Sterling, Khwankamon Rattanatumhi, Nattakarn Thippamom, Piyapha Hirunpatrawong, Pakamas Sangsub, Thaniwan Cheun-Arom, Dominic Esposito, Chee Wah Tan, Wee Chee Yap, Feng Zhu, Lin-Fa Wang, Eric D. Laing, Supaporn Wacharapluesadee, Opass Putcharoen

PMC · DOI: 10.3390/v17060837 · 2025-06-10

## TL;DR

This study tracks bat virus exposure in people who handle bat guano, finding rare long-lasting antibodies to MERS-CoV in one person.

## Contribution

First seroprevalence study of betacoronaviruses in bat guano workers before and after SARS-CoV-2 emergence.

## Key findings

- Pre-pandemic samples had no SARS-CoV-2 antibodies, but post-vaccination samples showed SARS-CoV-2 and related bat CoV antibodies.
- One participant had persistent MERS-CoV antibodies over four years despite no travel or severe illness history.
- Findings suggest possible MERS-CoV-like exposure in high-risk populations, highlighting need for ongoing surveillance.

## Abstract

Community-based serosurveillance for emerging zoonotic viruses can provide a powerful and cost-effective measurement of cryptic spillovers. Betacoronaviruses, including SARS-CoV, SARS-CoV-2 and MERS-CoV, are known to infect bats and can cause severe respiratory illness in humans, yet remain under-surveyed in high-risk populations. This study aimed to determine the seroprevalence of betacoronaviruses in an occupational cohort in contact with bats before and after the emergence of SARS-CoV-2. Serum samples from pre- and post-COVID-19 pandemic were screened using antigen-based multiplex microsphere immunoassays (MMIAs) and a multiplex surrogate virus neutralization test (sVNT). Pre-pandemic samples showed no SARS-CoV-2 antibodies, while post-pandemic samples from vaccinated participants displayed binding and neutralizing antibodies against SARS-CoV-2 and a related bat CoV. Furthermore, one participant (1/237, 0.43%) had persistent antibodies against MERS-CoV in 2017, 2018 and 2021 but was seronegative in 2023, despite reporting no history of traveling abroad or severe pneumonia. The observed sustained antibody levels indicate a possible exposure to MERS-CoV or a MERS-CoV-like virus, although the etiology and clinical relevance of this finding remains unclear. Ongoing surveillance in high-risk populations remains crucial for understanding virus epidemiology and mitigating zoonotic transmission risk.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382), respiratory illness (MESH:D012140), pneumonia (MESH:D011014)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009], Bacillus sp. AT (species) [taxon 1196779], Betacoronavirus (genus) [taxon 694002], Coronaviridae (family) [taxon 11118], Chiroptera (bats, order) [taxon 9397], Middle East respiratory syndrome-related coronavirus (no rank) [taxon 1335626]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12197454/full.md

---
Source: https://tomesphere.com/paper/PMC12197454